Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Malignant Lymphoma

  Free Subscription


09.05.2022

2 Am J Clin Pathol
3 Blood
1 BMC Cancer
1 Br J Dermatol
2 Br J Haematol
1 Eur J Haematol
1 Eur J Immunol
1 Exp Cell Res
4 Haematologica
1 J Clin Oncol
2 Leuk Lymphoma
2 Leukemia
1 Oncol Rep
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Clin Pathol

  1. OBIORAH IE, Wang HW, Ma D, Martin E, et al
    The Effectiveness of Dual-Staining Immunohistochemistry in the Detection of Mantle Cell Lymphoma in the Bone Marrow.
    Am J Clin Pathol. 2022;157:709-717.
    PubMed         Abstract available

  2. ALSUWAIDAN A, Koduru P, Fuda F, Manuel Jaso J, et al
    A Combined Biomarker of Bright CD38 and MYC >/=55% Is Highly Predictive of Double-/Triple-Hit High-Grade B-Cell Lymphoma.
    Am J Clin Pathol. 2022 May 3. pii: 6577222. doi: 10.1093.
    PubMed         Abstract available


    Blood

  3. CHERNG HJ, Sun R, Sugg B, Irwin R, et al
    Risk assessment with low pass whole genome sequencing of cell free DNA before CD19 CAR T-cells for large B-cell lymphoma.
    Blood. 2022 May 5. pii: 485178. doi: 10.1182/blood.2022015601.
    PubMed         Abstract available


  4. Lowe EJ, Reilly AF, Lim MS, et al. Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1. Blood. 2021;137(26):3595-3603.
    Blood. 2022;139:2726.
    PubMed        

  5. SONIGO G, Bozonnat A, Dumont M, Thonnart N, et al
    Involvement of the CD39/CD73/adenosine pathway in T-cell proliferation and NK cell-mediated antibody-dependent cell cytotoxicity in Sezary syndrome.
    Blood. 2022;139:2712-2716.
    PubMed        


    BMC Cancer

  6. LEGASON ID, Ogwang MD, Chamba C, Mkwizu E, et al
    A protocol to clinically evaluate liquid biopsies as a tool to speed up diagnosis of children and young adults with aggressive infection-related lymphoma in East Africa "(AI-REAL)".
    BMC Cancer. 2022;22:484.
    PubMed         Abstract available


    Br J Dermatol

  7. MITTELDORF C
    Multistaining for a better understanding of lymphoma biology.
    Br J Dermatol. 2022 May 4. doi: 10.1111/bjd.21590.
    PubMed        


    Br J Haematol

  8. DITTUS C, Miller JA, Wehbie R, Castillo JJ, et al
    Daratumumab with ifosfamide, carboplatin and etoposide for the treatment of relapsed plasmablastic lymphoma.
    Br J Haematol. 2022 May 4. doi: 10.1111/bjh.18228.
    PubMed        

  9. DIXON JG, Dimier N, Nielsen T, Zheng J, et al
    End of induction positron emission tomography complete response (PET-CR) as a surrogate for progression-free survival in previously untreated follicular lymphoma.
    Br J Haematol. 2022 May 2. doi: 10.1111/bjh.18217.
    PubMed         Abstract available


    Eur J Haematol

  10. VODICKA P, Benesova K, Janikova A, Prochazka V, et al
    Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world.
    Eur J Haematol. 2022 May 3. doi: 10.1111/ejh.13784.
    PubMed         Abstract available


    Eur J Immunol

  11. SUMMERAUER AM, Jaggi V, Ogwang R, Traxel S, et al
    Epstein-Barr virus and malaria upregulate AID and APOBEC3 enzymes, but only AID seems to play a major mutagenic role in Burkitt lymphoma.
    Eur J Immunol. 2022 May 3. doi: 10.1002/eji.202249820.
    PubMed         Abstract available


    Exp Cell Res

  12. NIE D, Xiao X, Chen J, Xie S, et al
    Prognostic and therapeutic significance of XPO1 in T-cell lymphoma.
    Exp Cell Res. 2022;416:113180.
    PubMed         Abstract available


    Haematologica

  13. PICOD A, Martino S, Cervera P, Manuceau G, et al
    Deregulated JAK3 mediates growth advantage and hemophagocytosis in extranodal nasal-type natural killer/T cell lymphoma.
    Haematologica. 2022 May 5. doi: 10.3324/haematol.2021.280349.
    PubMed         Abstract available

  14. MEI M, Hamadani M, Ahn KW, Chen Y, et al
    Autologous hematopoietic cell transplantation in diffuse large B-cell lymphoma after three or more lines of prior therapy: evidence of durable benefit.
    Haematologica. 2022;107:1214-1217.
    PubMed        

  15. ESCHERICH G, Zur Stadt U, Borkhardt A, Dilloo D, et al
    Clofarabine increases the eradication of minimal residual disease of primary B-precursor acute lymphoblastic leukemia compared to high-dose cytarabine without improvement of outcome. Results from the randomized clinical trial 08-09 of the Cooperative
    Haematologica. 2022;107:1026-1033.
    PubMed         Abstract available

  16. GAO J, Wang MY, Ren Y, Lwin T, et al
    Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas.
    Haematologica. 2022;107:1119-1130.
    PubMed         Abstract available


    J Clin Oncol

  17. MYERS RM, Taraseviciute A, Steinberg SM, Lamble AJ, et al
    Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL.
    J Clin Oncol. 2022;40:932-944.
    PubMed         Abstract available


    Leuk Lymphoma

  18. EVANS MG, Shestakova A, Haghighi N, Zhao X, et al
    Rare case of leptomeningeal small lymphocytic lymphoma with TP53 mutation detected by deep next-generation sequencing.
    Leuk Lymphoma. 2022 May 3:1-5. doi: 10.1080/10428194.2022.2070911.
    PubMed         Abstract available

  19. LEBEL E, Goldschmidt N, Siegal T, Lossos A, et al
    Rituximab, methotrexate, procarbazine and lomustine (R-MPL) for the treatment of primary Central nervous system lymphoma.
    Leuk Lymphoma. 2022 May 2:1-7. doi: 10.1080/10428194.2022.2064996.
    PubMed         Abstract available


    Leukemia

  20. ZHOU W, Xu Y, Zhang J, Zhang P, et al
    MiRNA-363-3p/DUSP10/JNK axis mediates chemoresistance by enhancing DNA damage repair in diffuse large B-cell lymphoma.
    Leukemia. 2022 Apr 29. pii: 10.1038/s41375-022-01565.
    PubMed         Abstract available

  21. KAMEDA K, Kako S, Kim SW, Usui Y, et al
    Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL.
    Leukemia. 2022;36:1361-1370.
    PubMed         Abstract available


    Oncol Rep

  22. LALIC H, Aurer I, Batinic D, Visnjic D, et al
    Bendamustine: A review of pharmacology, clinical use and immunological effects (Review).
    Oncol Rep. 2022;47.
    PubMed         Abstract available


    PLoS One

  23. KAWAHIRA M, Kanmura S, Mizuno K, Machida K, et al
    Effects of immune checkpoint inhibitor therapy resumption in patients with malignant tumors after moderate-to-severe immune-related adverse events.
    PLoS One. 2022;17:e0267572.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: